Xingqi Pharmaceutical: SQ-129 vitreous body sustained-release injection has obtained clinical trial approval
Xingqi Pharmaceutical announced that its developed SQ-129 vitreous sustained-release injection has received clinical trial approval from the National Medical Products Administration. This drug is a Class 2 modified new drug aimed at treating diabetic macular edema in adult patients and macular edema caused by retinal branch vein occlusion or central vein occlusion. Studies have shown that this drug has good safety and clinical development value, and currently, there are no similar products approved for market
According to the Zhitong Finance APP, Xingqi Pharmaceutical (300573.SZ) announced that it recently received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration for the SQ-129 vitreous sustained-release injection.
The SQ-129 vitreous sustained-release injection is a Class 2.2 modified new chemical drug developed by the company, intended for clinical use in (1) treating diabetic macular edema (DME) in adult patients; (2) treating macular edema caused by branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) in adult patients. In accordance with the relevant requirements for Class 2.2 modified new chemical drugs, the company has completed various studies on the SQ-129 vitreous sustained-release injection, including pharmaceutical and non-clinical pharmacology and toxicology studies. The research results indicate that the SQ-129 vitreous sustained-release injection has good safety and clinical development value. Currently, there are no approved products of this kind available in the domestic and international markets
